CN113710665A - 半乳糖凝集素-3的小分子抑制剂 - Google Patents
半乳糖凝集素-3的小分子抑制剂 Download PDFInfo
- Publication number
- CN113710665A CN113710665A CN202080027684.8A CN202080027684A CN113710665A CN 113710665 A CN113710665 A CN 113710665A CN 202080027684 A CN202080027684 A CN 202080027684A CN 113710665 A CN113710665 A CN 113710665A
- Authority
- CN
- China
- Prior art keywords
- disorders
- compound
- alkyl
- phenyl
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831753P | 2019-04-10 | 2019-04-10 | |
| US62/831,753 | 2019-04-10 | ||
| PCT/US2020/027203 WO2020210308A1 (en) | 2019-04-10 | 2020-04-08 | Small molecule inhibitors of galectin-3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113710665A true CN113710665A (zh) | 2021-11-26 |
Family
ID=70476468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080027684.8A Pending CN113710665A (zh) | 2019-04-10 | 2020-04-08 | 半乳糖凝集素-3的小分子抑制剂 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12269819B2 (https=) |
| EP (1) | EP3953349A1 (https=) |
| JP (1) | JP7577682B2 (https=) |
| KR (1) | KR102890853B1 (https=) |
| CN (1) | CN113710665A (https=) |
| WO (1) | WO2020210308A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| US12286424B2 (en) * | 2020-05-11 | 2025-04-29 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US12312362B2 (en) | 2020-10-06 | 2025-05-27 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of Alpha-D-galactopyranosides |
| EP4237419A1 (en) * | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| CN116806219A (zh) * | 2021-02-09 | 2023-09-26 | 爱杜西亚药品有限公司 | 羟基杂环烷-氨甲酰基衍生物 |
| RS67032B1 (sr) * | 2021-03-03 | 2025-08-29 | Idorsia Pharmaceuticals Ltd | Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| US9021050B2 (en) | 2012-08-31 | 2015-04-28 | Yume, Inc. | Network service system and method with off-heap caching |
| DK2906227T3 (en) | 2012-10-10 | 2018-12-10 | Galectin Therapeutics Inc | GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy |
| CN104755088A (zh) | 2012-10-31 | 2015-07-01 | 格莱克特生物技术公司 | 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用 |
| CA2970062C (en) | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| JP6844991B2 (ja) | 2015-11-10 | 2021-03-17 | サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスＳａｎｋｏ Ｔｅｋｓｔｉｌ Ｉｓｌｅｔｍｅｌｅｒｉ Ｓａｎ． Ｖｅ Ｔｉｃ． Ａ．Ｓ． | ジッパーを有する伸縮性衣類の製法 |
| KR20200015528A (ko) | 2017-05-12 | 2020-02-12 | 갈랙틴 사이언시즈, 엘엘씨 | 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도 |
| EP3621973A4 (en) | 2017-05-12 | 2021-10-27 | Galectin Sciences, LLC | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF |
| WO2019067702A1 (en) * | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
-
2020
- 2020-04-08 US US17/601,942 patent/US12269819B2/en active Active
- 2020-04-08 CN CN202080027684.8A patent/CN113710665A/zh active Pending
- 2020-04-08 EP EP20722856.0A patent/EP3953349A1/en active Pending
- 2020-04-08 KR KR1020217036227A patent/KR102890853B1/ko active Active
- 2020-04-08 WO PCT/US2020/027203 patent/WO2020210308A1/en not_active Ceased
- 2020-04-08 JP JP2021559883A patent/JP7577682B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022527395A (ja) | 2022-06-01 |
| US20220144818A1 (en) | 2022-05-12 |
| KR102890853B1 (ko) | 2025-11-24 |
| US12269819B2 (en) | 2025-04-08 |
| WO2020210308A1 (en) | 2020-10-15 |
| KR20210150485A (ko) | 2021-12-10 |
| EP3953349A1 (en) | 2022-02-16 |
| JP7577682B2 (ja) | 2024-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113710665A (zh) | 半乳糖凝集素-3的小分子抑制剂 | |
| JP6790183B2 (ja) | Ａｓｋ１阻害剤の固体形態 | |
| WO2024083258A1 (zh) | Kras g12d降解剂及其制备方法和应用 | |
| TWI657071B (zh) | 芳基醚及其用途 | |
| JP2023515404A (ja) | ヘテロ環ｇｌｐ－１アゴニスト | |
| CN117534685A (zh) | 一种pan-KRAS抑制剂化合物 | |
| TWI785474B (zh) | 用作選擇性Aurora A抑制劑的新型雜環化合物 | |
| TWI912419B (zh) | 羥肟酸酯化合物、其製備方法及其應用 | |
| TW201718561A (zh) | 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用 | |
| TW201609725A (zh) | 作為抗癌劑之新穎三環化合物 | |
| CN105008367A (zh) | 作为钾离子通道抑制剂的吡咯并三嗪类化合物 | |
| EA028821B1 (ru) | Соединения и способы для модуляции киназ, а также показания к их применению | |
| HUE035337T2 (en) | Macrocyclic compounds as TRK kinase inhibitors | |
| CN106413710A (zh) | 因子XIa抑制剂 | |
| TWI833819B (zh) | 用於治療與apj受體活性相關的病狀的化合物及組成物 | |
| JP7478165B2 (ja) | ガレクチン－３の低分子阻害剤 | |
| WO2020168939A1 (zh) | 杂环化合物、包含其的药物组合物及其制备方法和用途 | |
| CN111433207A (zh) | 作为αV整合素抑制剂的吡咯并吡嗪衍生物 | |
| CN111714628A (zh) | 小分子pd-1/pd-l1抑制剂、其与pd-l1抗体的药物组合物及其应用 | |
| WO2020259703A1 (zh) | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 | |
| CN108779115B (zh) | 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用 | |
| CN113336774B (zh) | 作为trk抑制剂的取代的手性二芳基大环化合物 | |
| CN112292386A (zh) | 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物 | |
| JP7772718B2 (ja) | ガレクチン－３阻害剤 | |
| HK40066473A (zh) | 用作选择性aurora a抑制剂的新型杂环化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |